On August 4, 2025, Novo Nordisk filed lawsuits against 12 compounding pharmacies in a single day. This wasn't a warning shot — it was a strategic shift. For the first time, the Danish pharmaceutical giant moved from targeting telehealth platforms and wellness centers to going directly after the pharmacies themselves.
Combined with more than 130 total federal complaints across 32 states, Novo's legal campaign represents the most aggressive enforcement effort in compounding pharmacy history. Here's what happened, who got sued, and why it matters.
The August 2025 Blitz
Novo Nordisk filed 12 lawsuits simultaneously, naming pharmacies including Axtell's Rite-Value Pharmacy and Link Pharmacy LLC. The core allegations were consistent across all filings: these pharmacies were marketing and selling non-FDA-approved injectable drugs claiming to contain semaglutide, using "unlawful, false, and misleading business practices."
The legal claims cited Lanham Act violations (false advertising and trademark infringement), state consumer protection law violations, and the allegation that pharmacies didn't tailor drugs to individual patient needs — meaning their products were "essentially copies" of Novo's commercially available Ozempic and Wegovy.
Why Pharmacies, Not Just Telehealth
Before August 2025, Novo had primarily targeted downstream: the telehealth companies and wellness centers selling compounded semaglutide to consumers. Going after the pharmacies that actually produce the medication was a tactical escalation. If you shut down the supply, the distribution collapses regardless of how many telehealth platforms exist.
The Bigger Campaign: 2024–2026
The August filings were just one chapter. Novo Nordisk's broader legal campaign includes more than 130 federal complaints in 40+ states, 44 permanent injunctions obtained against compounders, 14 new lawsuits filed in November 2025 alone, and the February 2026 patent infringement suit against Hims & Hers — the largest telehealth provider still selling compounded semaglutide.
The Hims & Hers Lawsuit (February 2026)
Novo's suit against Hims & Hers marked a new legal angle: patent infringement. Rather than just trademark and consumer protection claims, Novo alleged that Hims was violating active semaglutide patents by selling compounded versions. This was a significant strategic expansion — patent claims carry different remedies and can be harder to defend against than marketing disputes.
Hims responded aggressively, calling the lawsuit "a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care." Hims' stock dropped more than 18% on the news, while Novo's shares climbed 3%.
Quality Claims: What Novo Says It Found
Novo Nordisk has gone beyond legal arguments to make quality claims about compounded products. The company's testing of confiscated compounded semaglutide reportedly found products containing 24%+ impurities including unknown substances, instances of products labeled as semaglutide containing no semaglutide whatsoever, and use of unauthorized salt forms (semaglutide sodium) that haven't been studied for safety or efficacy.
These findings were submitted as evidence in multiple cases and have been cited by the FDA in its own enforcement actions.
The Florida Victory — and Its Limits
Not every case has gone Novo's way. In May 2025, a Florida federal court dismissed Novo's lawsuit against Brooksville Pharmaceuticals, ruling that Novo couldn't demonstrate consumer injury. However, the court's dismissal was narrow — it sidestepped the quality and safety questions entirely and focused on standing.
The Counter-Offensive
Compounders haven't simply accepted their legal fate. The most significant counterattack came from Strive Compounding Pharmacy, which filed an antitrust lawsuit against both Novo Nordisk and Eli Lilly in January 2026. Strive alleged a "coordinated effort to suppress competition" through exclusive agreements with telehealth platforms that barred those companies from working with compounders.
The Outsourcing Facilities Association also sued the FDA directly, challenging the agency's determination that semaglutide was no longer in shortage. While the 5th Circuit heard oral arguments in March 2026, no decision has been issued as of this writing.
Where Things Stand Now (May 2026)
| Development | Status | Impact |
|---|---|---|
| 130+ Novo lawsuits filed | 44 injunctions obtained | Many small pharmacies shuttered |
| Hims patent infringement suit | Active — early stages | Could cut off largest compounder |
| 5th Circuit OFA v. FDA appeal | Decision pending | Could restore shortage designation |
| Strive antitrust countersuit | Active | Could expose coordination |
| 503B Bulks List exclusion proposal | Comment period through June 29, 2026 | Would permanently end 503B compounding |
| Novo price cut to $675/mo | Effective Jan 1, 2027 | Reduces cost argument for compounding |
What This Means for You
If you're currently using compounded semaglutide, the practical impact depends entirely on your provider. Large, well-funded operations like Hims and Empower can absorb litigation costs and continue operating while cases proceed. Small 503A pharmacies operating with legitimate personalized prescriptions face less direct risk from Novo's campaign. Any provider making "essentially a copy" of Ozempic or Wegovy without genuine personalization is in the legal crosshairs.
The safest path forward: work with providers who are transparent about their pharmacy sourcing, hold active licenses, and can demonstrate genuine clinical reasons for compounding.
Our Take
Novo's lawsuit campaign is working. The combination of legal pressure, FDA enforcement, and upcoming regulatory changes (503B Bulks List exclusion, Novo's own price cuts) is systematically narrowing the compounding market. But it hasn't ended it — and the 5th Circuit ruling could still change the trajectory significantly.
Embody
Injectable compounded semaglutide from an FDA-registered 503B outsourcing facility. $149 first month, $299/mo ongoing. Includes prescriber consultation, medication, and shipping.
Paid link · Compounded medications are not FDA-approved products.
SkinnyRx
Three delivery formats — injectable, sublingual drops, and oral tablets — all from one provider. 503A compounding with LegitScript verification. Free physician consultation included.
Paid link · Compounded medications are not FDA-approved products.
GobyMeds
Semaglutide bundle from $99/mo, tirzepatide bundle from $133/mo. LegitScript-certified, 503A + 503B sourcing. Free consultation and free shipping. Use code x7X72r to save $25.
Paid link · Code x7X72r saves $25 · Compounded medications are not FDA-approved products.
Sesame Care
FDA-approved brand-name medications including Ozempic, Wegovy, Mounjaro, and Zepbound. Telehealth consultation with licensed providers. Prescriptions sent to your local pharmacy.
Get Started →Paid link · Sesame connects you with licensed providers for FDA-approved medications only.